|
1
|
Jamal-Hanjani M, Wilson GA, McGranahan N,
Birkbak NJ, Watkins TBK, Veeriah S, Shafi S, Johnson DH, Mitter R,
Rosenthal R, et al TRACERx Consortium, : Tracking the evolution of
non-small-cell lung cancer. N Engl J Med. 376:2109–2121. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Wakelee HA, Chang ET, Gomez SL, Keegan TH,
Feskanich D, Clarke CA, Holmberg L, Yong LC, Kolonel LN, Gould MK,
et al: Lung cancer incidence in never smokers. J Clin Oncol.
25:472–478. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ferlay J, Colombet M, Soerjomataram I,
Mathers C, Parkin DM, Piñeros M, Znaor A and Bray F: Estimating the
global cancer incidence and mortality in 2018: GLOBOCAN sources and
methods. Int J Cancer. 144:1941–1953. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Hu Z, Chen X, Zhao Y, Tian T, Jin G, Shu
Y, Chen Y, Xu L, Zen K, Zhang C, et al: Serum microRNA signatures
identified in a genome-wide serum microRNA expression profiling
predict survival of non-small-cell lung cancer. J Clin Oncol.
28:1721–1726. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Chen X, Ba Y, Ma L, Cai X, Yin Y, Wang K,
Guo J, Zhang Y, Chen J, Guo X, et al: Characterization of microRNAs
in serum: A novel class of biomarkers for diagnosis of cancer and
other diseases. Cell Res. 18:997–1006. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Casal-Mouriño A, Valdés L, Barros-Dios JM
and Ruano-Ravina A: Lung cancer survival among never smokers.
Cancer Lett. 451:142–149. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Vitsios DM, Davis MP, van Dongen S and
Enright AJ: Large-scale analysis of microRNA expression,
epi-transcriptomic features and biogenesis. Nucleic Acids Res.
45:1079–1090. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Iorio MV and Croce CM: MicroRNA
dysregulation in cancer: Diagnostics, monitoring and therapeutics.
A comprehensive review. EMBO Mol Med. 4:143–159. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Jin X, Chen Y, Chen H, Fei S, Chen D, Cai
X, Liu L, Lin B, Su H, Zhao L, et al: Evaluation of tumor-derived
exosomal miRNA as potential diagnostic biomarkers for early-stage
non-small cell lung cancer using next-generation sequencing. Clin
Cancer Res. 23:5311–5319. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Xia H, Li Y and Lv X: MicroRNA-107
inhibits tumor growth and metastasis by targeting the BDNF-mediated
PI3K/AKT pathway in human non-small lung cancer. Int J Oncol.
49:1325–1333. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Xie Y, Naizabekov S, Chen Z and Tokay T:
Power of PTEN/AKT: Molecular switch between tumor suppressors and
oncogenes. Oncol Lett. 12:375–378. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Sharma SS and Pledger WJ: The
non-canonical functions of p27 (Kip1) in normal and tumor biology.
Cell Cycle. 15:1189–1201. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Fenchel K, Sellmann L and Dempke WC:
Overall survival in non-small cell lung cancer - what is clinically
meaningful? Transl Lung Cancer Res. 5:115–119. 2016.PubMed/NCBI
|
|
15
|
Shepherd L, Ryom L, Law M, Petoumenos K,
Hatleberg CI, d'Arminio Monforte A, Sabin C, Bower M, Bonnet F,
Reiss P, et al Data Collection on Adverse Events of Anti-HIV Drugs
(D:A:D) Study Group, : Cessation of cigarette smoking and the
impact on cancer incidence in human immunodeficiency virus-infected
persons: The data collection on adverse events of anti-HIV drugs
study. Clin Infect Dis. 68:650–657. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kozub M, Gachewicz B, Kasprzyk M, Roszak
M, Gasiorowski L and Dyszkiewicz W: Impact of smoking history on
postoperative complications after lung cancer surgery - a study
based on 286 cases. Kardiochir Torakochirurgia Pol. 16:13–18.
2019.(In Polish). PubMed/NCBI
|
|
17
|
Sozzi G, Conte D, Leon M, Ciricione R, Roz
L, Ratcliffe C, Roz E, Cirenei N, Bellomi M, Pelosi G, et al:
Quantification of free circulating DNA as a diagnostic marker in
lung cancer. J Clin Oncol. 21:3902–3908. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhao W, Zhao JJ, Zhang L, Xu QF, Zhao YM,
Shi XY and Xu AG: Serum miR-21 level: A potential diagnostic and
prognostic biomarker for non-small cell lung cancer. Int J Clin Exp
Med. 8:14759–14763. 2015.PubMed/NCBI
|
|
19
|
Ha M and Kim VN: Regulation of microRNA
biogenesis. Nat Rev Mol Cell Biol. 15:509–524. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Carthew RW: Gene regulation by microRNAs.
Curr Opin Genet Dev. 16:203–208. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhu H, Chen W, Xu J, Yin L, Zhu H, Liu J,
Wang T and He X: MiR-21 expression significance in non-small cell
lung cancer tissue and plasma. Int J Clin Exp Med. 10:2918–2924.
2017.
|
|
22
|
Marsit CJ, Zheng S, Aldape K, Hinds PW,
Nelson HH, Wiencke JK and Kelsey KT: PTEN expression in
non-small-cell lung cancer: Evaluating its relation to tumor
characteristics, allelic loss, and epigenetic alteration. Hum
Pathol. 36:768–776. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Catzavelos C, Tsao MS, DeBoer G,
Bhattacharya N, Shepherd FA and Slingerland JM: Reduced expression
of the cell cycle inhibitor p27Kip1 in non-small cell lung
carcinoma: A prognostic factor independent of Ras. Cancer Res.
59:684–688. 1999.PubMed/NCBI
|
|
24
|
Liu ZL, Wang H, Liu J and Wang ZX:
MicroRNA-21 (miR-21) expression promotes growth, metastasis, and
chemo- or radioresistance in non-small cell lung cancer cells by
targeting PTEN. Mol Cell Biochem. 372:35–45. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhang JG, Wang JJ, Zhao F, Liu Q, Jiang K
and Yang GH: MicroRNA-21 (miR-21) represses tumor suppressor PTEN
and promotes growth and invasion in non-small cell lung cancer
(NSCLC). Clin Chim Acta. 411:846–852. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
David O: Akt and PTEN: New diagnostic
markers of non-small cell lung cancer? J Cell Mol Med. 5:430–433.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Arteaga CL: The epidermal growth factor
receptor: From mutant oncogene in nonhuman cancers to therapeutic
target in human neoplasia. J Clin Oncol. 19 (Suppl):S32–S40.
2001.
|
|
28
|
Yarden Y and Sliwkowski MX: Untangling the
ErbB signalling network. Nat Rev Mol Cell Biol. 2:127–137. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Wang DD, Ma L, Wong MP, Lee VH and Yan H:
Contribution of EGFR and ErbB-3 heterodimerization to the EGFR
mutation-induced gefitinib- and erlotinib-resistance in
non-small-cell lung carcinoma treatments. PLoS One.
10:e01283602015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Xu Y, Zong S, Gao X, Zhang H, Wang B, Li
P, Liu T and Li S: Combined treatment of ABT199 and irinotecan
suppresses KRAS-mutant lung cancer cells. Gene. 688:1–6. 2019.
View Article : Google Scholar : PubMed/NCBI
|
